Medicinal Chemistry Nature

Chimera jams AR and p300/CBP into a dead-end complex

  • DALTACs push two domains of endogenous proteins together in a non-native orientation instead of degrading them; DALTAC-1 joins the AR ligand-binding domain to the p300/CBP bromodomain.
  • The mismatched interface traps the complex in an unproductive state, shifting p300/CBP acetylation patterns and dismantling AR enhancer assemblies.
  • Reportedly it beats combined AR and p300/CBP inhibition, selectively in dual-dependent prostate cancer cells and with in vivo tumour responses.
Points Based on the abstract

Is this a degrader without the degradation? With no E3 ligase involved, SAR turns on linker geometry and the orientation it enforces, arguably harder to tune than ternary cooperativity in a PROTAC. Open questions are whether the AR-LBD binder is an agonist or antagonist and how selective the bromodomain binder is (BRD4 and other family members). Matched-linker inactive controls and structures of the forced interface would help.